| 000 | 01831 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250515015821.0 | ||
| 264 | 0 | _c20060601 | |
| 008 | 200606s 0 0 eng d | ||
| 022 | _a0302-282X | ||
| 024 | 7 |
_a10.1159/000091724 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMühlbacher, M | |
| 245 | 0 | 0 |
_aIntravenous mirtazapine is safe and effective in the treatment of depressed inpatients. _h[electronic resource] |
| 260 |
_bNeuropsychobiology _c2006 |
||
| 300 |
_a83-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntidepressive Agents, Tricyclic _xadministration & dosage |
| 650 | 0 | 4 |
_aDepressive Disorder, Major _xdiagnosis |
| 650 | 0 | 4 |
_aFatigue _xchemically induced |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeadache _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aInpatients |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMianserin _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMirtazapine |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aStatistics, Nonparametric |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVertigo _xchemically induced |
| 700 | 1 | _aKonstantinidis, A | |
| 700 | 1 | _aKasper, S | |
| 700 | 1 | _aEichberger, G | |
| 700 | 1 | _aHinterhuber, H | |
| 700 | 1 | _aHofmann, P | |
| 700 | 1 | _aNimmerrichter, A | |
| 700 | 1 | _aSchubert, H | |
| 700 | 1 | _aEgger, C | |
| 700 | 1 | _aNickel, M | |
| 700 | 1 | _aStuppaeck, C | |
| 773 | 0 |
_tNeuropsychobiology _gvol. 53 _gno. 2 _gp. 83-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000091724 _zAvailable from publisher's website |
| 999 |
_c16121627 _d16121627 |
||